Crossref journal-article
American Society for Microbiology
Journal of Virology (235)
Abstract

ABSTRACT Infection by some human immunodeficiency virus type 1 (HIV-1) isolates is enhanced by the binding of subneutralizing concentrations of soluble receptor, soluble CD4 (sCD4), or monoclonal antibodies directed against the viral envelope glycoproteins. In this work, we studied the abilities of different antibodies to mediate activation of the envelope glycoproteins of a primary HIV-1 isolate, YU2, and identified the regions of gp120 envelope glycoprotein contributing to activation. Binding of antibodies to a variety of epitopes on gp120, including the CD4 binding site, the third variable (V3) loop, and CD4-induced epitopes, enhanced the entry of viruses containing YU2 envelope glycoproteins. Fab fragments of antibodies directed against either the CD4 binding site or V3 loop also activated YU2 virus infection. The activation phenotype was conferred on the envelope glycoproteins of a laboratory-adapted HIV-1 isolate (HXBc2) by replacing the gp120 V3 loop or V1/V2 and V3 loops with those of the YU2 virus. Infection by the YU2 virus in the presence of activating antibodies remained inhibitable by macrophage inhibitory protein 1β, indicating dependence on the CCR5 coreceptor on the target cells. Thus, antibody enhancement of YU2 entry involves neither Fc receptor binding nor envelope glycoprotein cross-linking, is determined by the same variable loops that dictate enhancement by sCD4, and probably proceeds by a process fundamentally similar to the receptor-activated virus entry pathway.

Bibliography

Sullivan, N., Sun, Y., Binley, J., Lee, J., Barbas, C. F., Parren, P. W. H. I., Burton, D. R., & Sodroski, J. (1998). Determinants of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Activation by Soluble CD4 and Monoclonal Antibodies. Journal of Virology, 72(8), 6332–6338.

Authors 8
  1. Nancy Sullivan (first)
  2. Ying Sun (additional)
  3. James Binley (additional)
  4. Juliette Lee (additional)
  5. Carlos F. Barbas (additional)
  6. Paul W. H. I. Parren (additional)
  7. Dennis R. Burton (additional)
  8. Joseph Sodroski (additional)
References 83 Referenced 124
  1. 10.1126/science.272.5270.1955
  2. 10.1126/science.1925547
  3. 10.1126/science.2309120
  4. 10.1006/jmbi.1993.1203
  5. 10.1126/science.6189183
  6. 10.1128/jvi.66.4.2389-2397.1992
  7. Bugelski P. J. Ellens H. Hart T. K. Kirsh R. L. Soluble CD4 and dextran sulfate mediate release of gp120 from HIV-1: implications for clinical trials.J. Acquired Immune Defic. Syndr. 4 1991 923 924 / J. Acquired Immune Defic. Syndr. / Soluble CD4 and dextran sulfate mediate release of gp120 from HIV-1: implications for clinical trials by Bugelski P. J. (1991)
  8. 10.1073/pnas.88.22.10134
  9. 10.1126/science.7973652
  10. 10.1006/viro.1993.1664
  11. 10.1128/jvi.71.4.2705-2714.1997
  12. 10.1016/S0092-8674(00)81313-6
  13. 10.1128/jvi.66.6.3531-3537.1992
  14. Connor R. I. Dinces N. B. Howell A. L. Romet-Lemonne J. L. Pasquali J. L. Fanger M. W. Fc receptors for IgG (Fc gamma Rs) on human monocytes and macrophages are not infectivity receptors for human immunodeficiency virus type 1 (HIV-1): studies using bispecific antibodies to target HIV-1 to various myeloid cell surface molecules, including the Fc gamma R.Proc. Natl. Acad. Sci. USA 88 1991 9593 9597 (10.1073/pnas.88.21.9593) / Proc. Natl. Acad. Sci. USA / Fc receptors for IgG (Fc gamma Rs) on human monocytes and macrophages are not infectivity receptors for human immunodeficiency virus type 1 (HIV-1): studies using bispecific antibodies to target HIV-1 to various myeloid cell surface molecules, including the Fc gamma R by Connor R. I. (1991)
  15. 10.1006/viro.1995.1212
  16. 10.1038/381661a0
  17. 10.1006/jmbi.1997.0912
  18. 10.1016/S0092-8674(00)81314-8
  19. 10.1038/381667a0
  20. 10.1073/pnas.87.2.648
  21. 10.1097/00002030-199305000-00005
  22. 10.1016/S0092-8674(00)81393-8
  23. 10.1126/science.272.5263.872
  24. 10.1128/jvi.66.5.3183-3187.1992
  25. 10.1128/jvi.71.4.2779-2785.1997
  26. 10.1128/jvi.67.7.3818-3825.1993
  27. 10.1016/0092-8674(87)90485-5
  28. 10.1089/aid.1989.5.431
  29. 10.1126/science.6200936
  30. 10.1084/jem.184.6.2433
  31. 10.1006/viro.1995.1367
  32. 10.1073/pnas.88.6.2189
  33. 10.1038/385645a0
  34. 10.1128/jvi.64.5.2416-2420.1990
  35. 10.1128/jvi.64.12.6314-6318.1990
  36. 10.1016/0042-6822(92)90444-T
  37. 10.1016/0923-2516(91)90055-8
  38. 10.1089/aid.1990.6.1209
  39. 10.1128/jvi.68.4.2253-2259.1994
  40. 10.1126/science.3629244
  41. 10.1128/jvi.66.11.6587-6600.1992
  42. 10.1128/jvi.65.8.3973-3985.1991
  43. 10.1038/343659a0
  44. 10.1128/jvi.69.1.101-109.1995
  45. Moore J. P. and D. D. Ho. 1995. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS 9 (Suppl. A) : S117–S136.
  46. 10.1089/aid.1992.8.443
  47. 10.1128/jvi.65.3.1133-1140.1991
  48. 10.1126/science.2251501
  49. Moore J. P. and P. L. Nara. 1991. The role of the V3 loop of gp120 in HIV infection. AIDS 5 (Suppl. 2) : S21–S33. (10.1097/00002030-199101001-00004)
  50. 10.1128/jvi.70.3.1863-1872.1996
  51. 10.1089/aid.1997.13.1291
  52. 10.1128/jvi.68.8.5264-5269.1994
  53. 10.1128/jvi.70.6.3407-3415.1996
  54. 10.1159/000319346
  55. 10.1128/JVI.72.5.3512-3519.1998
  56. 10.1126/science.6200935
  57. 10.1089/aid.1987.3.387
  58. 10.1128/jvi.62.7.2258-2264.1988
  59. 10.1128/jvi.71.4.3219-3227.1997
  60. 10.1128/jvi.68.8.4821-4828.1994
  61. 10.1084/jem.174.2.407
  62. 10.1098/rstb.1993.0136
  63. 10.1084/jem.182.1.185
  64. 10.1128/jvi.67.12.7383-7393.1993
  65. 10.1089/aid.1993.9.159
  66. 10.1111/j.1365-3083.1995.tb03528.x
  67. 10.1099/0022-1317-78-5-999
  68. 10.1016/0161-5890(96)00044-2
  69. 10.1128/jvi.70.12.8355-8360.1996
  70. 10.1126/science.6204380
  71. 10.1006/viro.1997.8443
  72. 10.1128/JVI.72.6.4694-4703.1998
  73. 10.1128/jvi.69.7.4413-4422.1995
  74. 10.1128/jvi.67.6.3674-3679.1993
  75. 10.1128/jvi.64.11.5605-5610.1990
  76. 10.1128/jvi.66.9.5516-5524.1992
  77. 10.1128/jvi.67.7.3978-3988.1993
  78. 10.1038/384184a0
  79. 10.1073/pnas.85.24.9580
  80. 10.1128/jvi.68.2.1029-1039.1994
  81. 10.1038/384179a0
  82. 10.1128/jvi.69.9.5723-5733.1995
  83. 10.1128/jvi.67.8.4557-4565.1993
Dates
Type When
Created 5 years, 7 months ago (Dec. 31, 2019, 1:16 p.m.)
Deposited 3 years, 5 months ago (March 4, 2022, 10:02 p.m.)
Indexed 1 month, 1 week ago (July 14, 2025, 11:26 p.m.)
Issued 27 years ago (Aug. 1, 1998)
Published 27 years ago (Aug. 1, 1998)
Published Print 27 years ago (Aug. 1, 1998)
Funders 0

None

@article{Sullivan_1998, title={Determinants of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Activation by Soluble CD4 and Monoclonal Antibodies}, volume={72}, ISSN={1098-5514}, url={http://dx.doi.org/10.1128/jvi.72.8.6332-6338.1998}, DOI={10.1128/jvi.72.8.6332-6338.1998}, number={8}, journal={Journal of Virology}, publisher={American Society for Microbiology}, author={Sullivan, Nancy and Sun, Ying and Binley, James and Lee, Juliette and Barbas, Carlos F. and Parren, Paul W. H. I. and Burton, Dennis R. and Sodroski, Joseph}, year={1998}, month=aug, pages={6332–6338} }